Compare OWLT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OWLT | BOLD |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.4M | 60.8M |
| IPO Year | 2020 | 2024 |
| Metric | OWLT | BOLD |
|---|---|---|
| Price | $5.06 | $2.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 162.2K | 110.7K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $105,708,000.00 | N/A |
| Revenue This Year | $13.29 | N/A |
| Revenue Next Year | $20.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.43 | N/A |
| 52 Week Low | $4.19 | $0.96 |
| 52 Week High | $16.94 | $3.16 |
| Indicator | OWLT | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 30.09 |
| Support Level | $5.18 | $2.39 |
| Resistance Level | $5.57 | $2.64 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 72.48 | 13.73 |
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.